Published in Lab Law Weekly, March 2nd, 2007
Of the total pharmaceutical sales, Xopenex brand levalbuterol HCl inhalation solution revenues were $179.9 million, Xopenex HFA brand levalbuterol tartrate inhalation aerosol MDI revenues were $20.9 million, and Lunesta brand eszopiclone revenues were $148.0 million.
Net income for the fourth quarter of 2006 was approximately $99.1 million. Reported results for the fourth quarter of 2006 included charges of $13.8 million...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Lab Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.